Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into an agreement with BliNK Biomedical for an exclusive commercial license to certain antibodies targeting CD47, for potential development and commercialization into novel bispecific therapeutics created via Genmab’s proprietary DuoBody Platform technology. This agreement supports Genmab’s established product pipeline strategy. Under the terms of the agreement, Genmab will pay BliNK Biomedical an upfront fee of USD 2.25 million. BliNK Biomedical is also eligible to receive up to approximately USD 200 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales. [...]